ClinicalTrials.gg
RecruitingNCT07519655Updated Nov 5, 2026

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

A Phase 1 interventional study of PF-08046033 in Non-Small-Cell Lung, Esophageal Cancer and Cutaneous Melanoma, sponsored by Pfizer. Recruiting at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 5, 2026First sites in France, Spain and NetherlandsSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Esophageal Neoplasms by Pfizer — 4 open to participants now, 5 under way, none of them phase 3. Esophageal Neoplasms · Pfizer.

Planned enrollment
4th of 12
250 · median 100
Started
2026
with 1 other
Phase 1
8 of 12
4 open now
Registered
11th of 12
by date

Among the 12 studies in Esophageal Neoplasms by Pfizer, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 1, and was the 11th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

4 of the 12 studies in Esophageal Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Esophageal Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer.

The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma.

The study has two parts:

In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing.

Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer.

Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.

03

Conditions studied

  • Non-Small-Cell Lung
  • Esophageal Cancer
  • Cutaneous Melanoma

Keywords

  • Lung cancer
  • Esophageal cancer
  • Melanoma
  • Antibody drug conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have -confirmed or unresectable locally advanced NSCLC, ESCC, or cutaneous melanoma.
  2. Participants must have disease that has progressed on or be unable to tolerate standard treatments (Part 1) or 1-2 prior systemic therapies (Part 2).
  3. Participants must have .
  4. (ECOG) performance status is 0-1.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known clinically active central nervous system (CNS) .
  2. Participants with pre-existing neuropathy ≥Grade 2 per v 5.0.
  3. Uncontrolled diabetes mellitus with (Hgb) ≥10.0%.
  4. Untreated thromboembolic disease.
  5. Previous exposure to GPNMB-targeted therapy.
  6. Known or suspected to any component or contained in the drug formulation of study intervention.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Part 1: Cohort 1

    Participants will receive PF-08046033 dose level 1 intravenously (IV).

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 2

    Participants will receive PF-08046033 dose level 2 IV.

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 3

    Participants will receive PF-08046033 dose level 3 IV.

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 4

    Participants will receive PF-08046033 dose level 4 IV.

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 5

    Participants will receive PF-08046033 dose level 5 IV.

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 6

    Participants will receive PF-08046033 dose level 6 IV.

    Drug: PF-08046033

  • Experimental
    Part 1: Cohort 7

    Participants will receive PF-08046033 dose level 7 IV.

    Drug: PF-08046033

  • Experimental
    Part 2: Cohort 1 Non-Small Cell Lung Cancer (NSCLC)

    PF-08046033: Specified dose IV on specified days

    Drug: PF-08046033

  • Experimental
    Part 2: Cohort 2 Esophageal Squamous Cell Carcinoma (ESCC)

    PF-08046033: Specified dose IV on specified days

    Drug: PF-08046033

  • Experimental
    Part 2: Cohort 3 (Cutaneous Melanoma)

    PF-08046033: Specified dose IV on specified days

    Drug: PF-08046033

Interventions

  • DrugPF-08046033

    Powder for solution for infusion.

06

What researchers measure

Primary outcomes

  1. Type, incidence and severity of participants with adverse events (AEs)

    Type, incidence, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v 5.0), seriousness, and relatedness of adverse events (AEs).

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 1 year

  2. Type, incidence, and severity of participants with laboratory abnormalities

    Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 1 year

  3. Number of participants with dose modifications

    Frequency of dose modifications (eg, dose delay and treatment discontinuations) due to AEs

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 1 year

  4. Incidence of dose-limiting toxicities (DLTs)

    To identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) of PF-08046033

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 1 year

  5. Recommended dose and schedule of PF-08046033 for expansion (RDE)

    RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings

    Time frame: Up to 1 year

Secondary outcomes

  1. Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by investigator

    Objective response defined as Complete Response (CR) or Partial Response (PR) per RECIST v1.1, from the date of first dose until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurs first.

    Time frame: Up to 3 years

  2. Duration of response (DOR) using RECIST v1.1 as assessed by investigator

    DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

    Time frame: Up to 3 years

  3. Progression-free survival (PFS) using RECIST v1.1 as assessed by investigator

    Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective progressive disease (PD) assessed by investigator per RECIST 1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 3 years

  4. Overall survival (OS) using RECIST v1.1 as assessed by investigator

    Overall survival defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to 3 years

  5. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of PF-08046033

    To characterize the PK of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, , Up to approximately 1 year

  6. PK: Area under the concentration-time curve (AUC) of PF-08046033

    To characterize the PK of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

  7. PK: Time to Maximum concentration (Tmax) of PF-08046033

    To characterize the PK of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

  8. PK: Trough concentration (Ctrough) of PF-08046033

    To characterize the PK of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

  9. PK: Terminal Elimination half-life (t1/2) of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

  10. Incidence of antidrug antibodies (ADAs)

    To characterize the immunogenicity of PF-08046033

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

  11. Percent change of immune cells and PD-L1 expression based on immunohistochemistry

    To evaluate the pharmacodynamic effects of PF-08046033 in tumor tissue

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until End of Treatment, Up to approximately 1 year

07

Study locations

20 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

Of 78 industry-sponsored phase 1 interventional studies under Esophageal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 70. This study's planned 27 months is below that.

Counting every sponsor, half of 126 studies reached it within 48 months; a quarter within 29 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 9, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Jul 14, 2028
CompletionEst.
Jul 14, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in France, Spain and Netherlands. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Gustave Roussy · Villejuif, FranceNot yet recruiting→Recruiting
  • Oncopole Claudius Regaud · Toulouse, FranceNot yet recruiting→Recruiting
  • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
  • Severance Hospital, Yonsei University Health System · Seoul, South KoreaNot yet recruiting→Recruiting
Show 6 added (2 France, 2 Spain, 1 South Korea, 1 Netherlands)
  • Oncopole Claudius Regaud · Toulouse, France
  • Gustave Roussy · Villejuif, France
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) · Amsterdam, Netherlands
across 4 updates, Sep 28, 2026 – Nov 5, 2026
Show all 4 updates
  1. Nov 5, 2026
    1 site added — first site in Netherlands. Severance Hospital, Yonsei University Health System is now Recruiting
    Show site
    • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) · Amsterdam, Netherlands
    + 1 other change: verification date
  2. Oct 13, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Oncopole Claudius Regaud · Toulouse, FranceNot yet recruiting→Recruiting
    • Hospital Universitari Vall d'Hebron · Barcelona, SpainNot yet recruiting→Recruiting
  3. Oct 6, 2026
    Gustave Roussy is now Recruiting
    + 1 other change: verification date
  4. Sep 28, 2026
    5 sites added — first sites in France and Spain
    Show 5 added (2 France, 2 Spain, 1 South Korea)
    • Oncopole Claudius Regaud · Toulouse, France
    • Gustave Roussy · Villejuif, France
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07519655
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 8, 2026
Primary completion
Jul 14, 2028 (estimated)
Completion
Jul 14, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion